Is Egrifta (Tesamorelin) Legal in Texas?

What Is Tesamorelin and Why Does Its Legal Category Matter?

Tesamorelin is a stabilized synthetic analog of endogenous growth-hormone-releasing hormone (GHRH). It stimulates the pituitary to release growth hormone in a pulsatile, physiologic pattern rather than supplying exogenous GH directly. That mechanism is clinically significant. It is also legally significant because tesamorelin is not classified as a controlled substance or as human growth hormone (HGH) under the Anabolic Steroid Control Act, which means the stricter scheduling rules that apply to HGH do not apply here.

The FDA approved the original Egrifta formulation in December 2010 under NDA 022505, followed by the reformulated Egrifta SV (2 mg/vial) in 2019. The full current prescribing information is available on the FDA accessdata portal.

Understanding that distinction upfront matters for Texas patients: the legal pathway to access depends entirely on which formulation you are seeking (brand, compounded, or research-grade) and which clinical indication your prescriber documents.

The Federal vs. State Regulatory Split

Drug legality in the United States runs on two parallel tracks. Federal law (the Food, Drug, and Cosmetic Act, the Controlled Substances Act, and FDA regulations) sets the floor. State law adds requirements on top. Texas does not preempt or contradict federal drug law for tesamorelin. Both systems must be satisfied simultaneously.

For a Texas patient, that means three questions must each be answered yes before a prescription is fully lawful:

1. Is the drug federally legal to prescribe?
2. Does a Texas-licensed prescriber hold a valid license and prescribing authority?
3. Is the pharmacy dispensing the product compliant with either FDA and TSBP regulations?

Tesamorelin clears all three hurdles when the chain of custody is properly structured.

Federal Legal Status of Tesamorelin

Tesamorelin is an FDA-approved prescription drug. It is not a controlled substance under the federal Controlled Substances Act (21 U.S.C. § 812). It does not appear on the FDA's list of bulk drug substances that may not be compounded (the so-called "Category 2 bulks" list under Section 503A of the FD&C Act). The FDA's current 503A bulk drug substances list is maintained here.

FDA-Approved Indication

The single FDA-approved indication for tesamorelin is reduction of excess abdominal fat in HIV-infected adults with lipodystrophy. The key phase III program supporting that approval included two randomized, double-blind trials (combined N=816). In those trials, tesamorelin 2 mg subcutaneously daily produced a statistically significant reduction in visceral adipose tissue versus placebo at 26 weeks (trunk fat reduction approximately 18% vs. Approximately 5% placebo; P<0.001). See the primary efficacy publication on PubMed.

The FDA approval does not restrict which patients a licensed U.S. Physician may prescribe tesamorelin to. Off-label prescribing is a legal medical practice under federal law, provided the prescriber documents the clinical rationale. The American Association of Clinical Endocrinology (AACE) 2023 clinical practice guidelines on growth hormone deficiency acknowledge GHRH analogs as mechanistically distinct from exogenous GH and do not prohibit their off-label use. AACE guidelines are available at aace.com.

Compounded Tesamorelin: The 503A vs. 503B Framework

This is where the legal picture requires precision. Brand-name Egrifta is commercially available and fully legal to prescribe and dispense in Texas through licensed pharmacies. Compounded tesamorelin is legal, but only under specific conditions.

503A pharmacies are traditional compounding pharmacies that prepare patient-specific prescriptions. They may compound tesamorelin because it is not on the FDA's prohibited bulks list and not on the list of drugs that have been withdrawn from the market for safety reasons. The compounded product cannot be a copy of a commercially available drug, which introduces a nuance: a prescriber must document a clinical difference (e.g., different concentration, different vehicle, documented allergy to an excipient in Egrifta SV) to justify compounding when brand-name Egrifta is available. FDA guidance on 503A compounding is at fda.gov.

503B outsourcing facilities produce larger batches without patient-specific prescriptions and are subject to Current Good Manufacturing Practice (cGMP) standards. They may compound tesamorelin for office use by licensed prescribers, again provided the product is not a copy of a commercially available approved drug.

The practical clinical framework for compounded tesamorelin access in Texas looks like this:

| Route | Requires Patient-Specific Rx? | Requires Clinical Differentiation from Brand? | Regulatory Oversight | |---|---|---|---| | Brand Egrifta SV (2 mg) | Yes | N/A | FDA NDA + TSBP dispensing rules | | 503A compounded | Yes | Yes, documented | FDA 503A + TSBP compounding rules | | 503B outsourcing facility | No (office use) | Yes, documented | FDA 503B cGMP + TSBP | | Research-chemical "peptide" (unlicensed) | N/A | N/A | Not legal for human use |

The bottom row deserves emphasis. Tesamorelin sold online as a "research chemical" or "not for human use" is not legal for patient administration in Texas or any other state. Administering it is a violation of federal FD&C Act misbranding and adulteration statutes.

Texas State Legal Framework

Texas Health and Safety Code: Controlled Substances

Texas Health and Safety Code Chapter 481 adopts the federal controlled substance schedules and adds Texas-specific schedules. Tesamorelin does not appear in any Texas schedule. It is a legend drug (prescription-only) under both federal and Texas law, meaning it requires a valid prescription but carries no additional state scheduling burden.

The Texas Department of State Health Services (DSHS) maintains the Texas controlled substances schedules. The current schedules are published at dshs.texas.gov.

Texas State Board of Pharmacy Compounding Rules

The Texas State Board of Pharmacy (TSBP) regulates all pharmacy practice in the state, including compounding. TSBP rules align with federal 503A and 503B frameworks. A Texas-licensed 503A pharmacy may prepare tesamorelin for an individual patient provided:

• A valid prescription from a Texas-licensed (or out-of-state licensed with Texas authority) prescriber exists.
• The pharmacy holds an active TSBP pharmacy license.
• The compounding does not violate FDA's commercial copy prohibition.
• Sterile compounding is performed under USP Chapter 797 standards, which govern sterile preparations. USP 797 standards are referenced in TSBP Rule 291.133.

Texas does not impose additional restrictions on which peptide active pharmaceutical ingredients (APIs) a licensed 503A pharmacy may compound beyond what federal law requires. TSBP Rule 291.131 through 291.135 cover sterile and non-sterile compounding; none exclude tesamorelin specifically.

Texas Medical Practice Act and Off-Label Prescribing

Texas Occupations Code Chapter 151 (the Medical Practice Act) governs physician prescribing authority. Texas physicians may prescribe FDA-approved drugs for any medically indicated use, including off-label applications, provided the prescriber exercises appropriate clinical judgment and documents the indication. The Texas Medical Board has not issued any guidance restricting off-label prescribing of tesamorelin.

A 2023 position statement from the Endocrine Society on growth hormone and GHRH therapy notes that off-label use of tesamorelin "requires documentation of visceral adiposity, growth hormone deficiency, or related metabolic dysfunction and informed patient consent," which is standard practice language applicable in Texas. Endocrine Society clinical resources are at endocrine.org.

How to Get Egrifta (Tesamorelin) in Texas

Step 1: Consult a Licensed Texas Prescriber

Any MD, DO, NP (with prescriptive authority), or PA (with supervising physician agreement) licensed in Texas may prescribe tesamorelin. The prescriber must conduct a proper evaluation, document the clinical indication, and issue a valid written or electronic prescription. Texas allows prescribers to evaluate patients via telemedicine for non-controlled legend drugs under Texas Occupations Code § 111.005, meaning an in-person visit is not mandatory for initial evaluation, though some prescribers require it.

Step 2: Obtain Baseline Labs

Most competent prescribers will order baseline labs before initiating tesamorelin. Standard panels include:

• Fasting IGF-1 (to assess GH axis status)
• Fasting glucose and HbA1c (tesamorelin can raise glucose; the Egrifta SV label carries a glucose-monitoring warning)
• Fasting lipid panel
• Liver function tests
• For HIV-associated lipodystrophy: DXA or CT scan to quantify visceral adipose tissue

The Egrifta SV prescribing information specifically warns that tesamorelin may cause glucose intolerance and increase the risk of diabetes mellitus. Full prescribing information at FDA accessdata. Patients with active malignancy, known pituitary tumor, or hypopituitarism due to structural damage are contraindicated.

Step 3: Source from a Compliant Pharmacy

Texas patients have three lawful sourcing options:

Option A: Brand Egrifta SV. Prescribed through a retail or specialty pharmacy. Theratechnologies, the manufacturer, operates a patient support program. Brand pricing without insurance can exceed $3,000 per month; prior authorization is commonly required for commercial insurance and HIV-specific programs (e.g., ADAP formularies) may cover it for the approved indication.

Option B: 503A Compounded Tesamorelin. Sourced from a TSBP-licensed sterile compounding pharmacy. Typically costs $150 to $400 per month depending on dose and formulation. The prescriber must document clinical justification for compounding.

Option C: 503B Outsourcing Facility Supply. A prescribing clinic may stock tesamorelin from a federally registered 503B facility for in-office administration or dispensing.

Patients should verify that any compounding pharmacy holds an active TSBP license (searchable at tsbp.texas.gov) and, for 503B facilities, an FDA registration (searchable at fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities).

Step 4: Understand the Dosing Protocol

The FDA-approved dose for HIV-associated lipodystrophy is tesamorelin 2 mg subcutaneous injection once daily. Off-label protocols used by clinicians for other indications vary; doses of 1 mg to 2 mg daily are commonly described in the peer-reviewed literature. A 26-week randomized trial published in the Journal of Clinical Endocrinology and Metabolism (N=61, non-HIV adults with abdominal obesity) found that tesamorelin 2 mg/day reduced visceral adipose tissue by 18.4% compared with 5.0% for placebo (P<0.001) over 26 weeks. See that study on PubMed.

Therapy is typically evaluated at 12 weeks; if no meaningful response is documented, the Egrifta SV label recommends reassessing continuation.

Practical Compliance Checklist for Texas Patients

Patients and prescribers in Texas should confirm the following before starting tesamorelin:

• Prescriber holds an active Texas medical license and has conducted a documented evaluation.
• Prescription is written for a specific indication with the patient's name, dose, quantity, and refill information.
• Pharmacy is actively licensed by TSBP (for compounded) or is a licensed retail/specialty pharmacy (for brand).
• Baseline labs are on file.
• Patient has signed an informed consent documenting understanding of on-label vs. Off-label status and glucose-monitoring requirements.
• No active malignancy, untreated pituitary pathology, or pregnancy (tesamorelin is Pregnancy Category X).

The Endocrine Society's 2019 guidelines on adult GH deficiency state: "Clinicians should individualize GH-axis therapy based on documented biochemical deficiency, symptom burden, and metabolic risk profile, with re-evaluation at 6-month intervals." See the guideline at pubmed.ncbi.nlm.nih.gov.

What Is Not Legal in Texas

Two situations fall clearly outside the legal boundary:

Unlicensed online sellers. Websites offering tesamorelin as a "research chemical" or "for laboratory use only" with no prescription requirement are selling a misbranded and adulterated product under federal law. Purchasing from these sources exposes the buyer to unknown purity, incorrect dosing, microbial contamination, and federal legal risk.

Self-administration without a prescription. Administering a legend drug to oneself without a valid prescription is a Class A misdemeanor under Texas Health and Safety Code § 483.041, which covers dangerous drugs (non-controlled prescription drugs). Tesamorelin, as an injectable legend drug, falls under that statute.

Prescribing across state lines without Texas authority. An out-of-state physician who has not registered with the Texas Medical Board (or obtained a special purpose license or used the IMLC compact pathway, which Texas joined in 2019) cannot legally prescribe to a Texas patient, even via telehealth.